Pfizer to expand respiratory drug portfolio with ReViral acquisition

The US drugmaker is to acquire Britain's ReViral for around $525m, to gain access to experimental drugs against the respiratory syncytial virus. ReViral has four RSV therapies in its pipeline, with lead product candidate Sisunatovir in mid-stage studies.

Read the full article.